ELICITATION WITHIN EHTA: POTENTIAL EFFICACY OF MELATONIN MEDICATION FOR STEMI PATIENTS WITH DETECTED HIGH RISK OF REPERFUSION VENTRICULAR FIBRILLATION DURING PCI
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68407700%3A21460%2F24%3A00382218" target="_blank" >RIV/68407700:21460/24:00382218 - isvavai.cz</a>
Result on the web
<a href="https://doi.org/10.14311/CTJ.2024.4.01" target="_blank" >https://doi.org/10.14311/CTJ.2024.4.01</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.14311/CTJ.2024.4.01" target="_blank" >10.14311/CTJ.2024.4.01</a>
Alternative languages
Result language
angličtina
Original language name
ELICITATION WITHIN EHTA: POTENTIAL EFFICACY OF MELATONIN MEDICATION FOR STEMI PATIENTS WITH DETECTED HIGH RISK OF REPERFUSION VENTRICULAR FIBRILLATION DURING PCI
Original language description
Patients with acute ST-segment elevation myocardial infarction (STEMI) have a high risk of ventricular fibrillation. The aim of the study is to determine an unknown parameter of the new diagnostic cardiology technology model created within eHTA, effectiveness of intravenous administration of high doses of melatonin (4mg/kg) before/during PCI as protective medication in STEMI patients with a diagnosed by new technology high risk of ventricular fibrillation at reperfusion using expert elicitation. Ten experts took part in the elicitation and filled out prepared questionnaire, which included experimental evidence for antiarrhythmic action of melatonin, including cellular mechanisms. They expressed their opinions on the potential effectiveness of medication using numerical method and also answered questions about the suitability of the dosage, adverse effects and the risk-benefit ratio. Experts' answers to the main research question were weighted based on their experience. Elicitation revealed the effectiveness value of 71.82% for the tested medication. Eighty percent of experts agreed that the dose is adequate, that side effects will be minimal, and that the benefits of such therapy outweigh possible risks. Results of this study will be applied for eHTA of novel diagnostic technology in cardiology and will help its manufacturer to evaluate the clinical effectiveness of the technology, find the right direction to complete the design and development of medical device, achieve optimal efficiency, present the concept and find investors, prepare for clinical evaluation, CE certification and inclusion to reimbursement system.
Czech name
—
Czech description
—
Classification
Type
J<sub>SC</sub> - Article in a specialist periodical, which is included in the SCOPUS database
CEP classification
—
OECD FORD branch
30300 - Health sciences
Result continuities
Project
—
Continuities
S - Specificky vyzkum na vysokych skolach
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Lékař a technika – Clinician and Technology
ISSN
0301-5491
e-ISSN
2336-5552
Volume of the periodical
54
Issue of the periodical within the volume
4
Country of publishing house
CZ - CZECH REPUBLIC
Number of pages
8
Pages from-to
111-118
UT code for WoS article
—
EID of the result in the Scopus database
2-s2.0-105001137693